drugset / Trial / NCT06756334
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
NaSingle-groupOpen-labelDiagnostic
Summary
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-DCFPyL.
Timeline
- Start
- 2024-12-19
- Primary completion
- 2025-06-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]AlF-PSMA-N5 | Diagnostic / imaging agent | — | Intravenous |
| Subject | [18F]F-DCFPyL | Unknown | — | Intravenous |